BI
RPRX icon

Binnacle Investments’s Royalty Pharma RPRX Stock Holding History

Binnacle Investments’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$847 Buy
+24
New +$869 ﹤0.01% 779

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Binnacle Investments's RPRX Position: Q3 2025 in Review

Binnacle Investments opened a new position in Royalty Pharma (RPRX) in Q3 2025: 24 shares worth $847. The stake represents ﹤0.01% of the portfolio and ranks #779 among its holdings.

487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • Binnacle Investments held 24 shares of Royalty Pharma worth $847 as of Q3 2025.
  • Royalty Pharma was a new Binnacle Investments position in Q3 2025.
  • Royalty Pharma made up ﹤0.01% of Binnacle Investments's portfolio in Q3 2025, its #779 holding.
  • 487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.